About
About Interdict Bio
Interdict Bio develops small molecule inhibitors called Interdictors™ that inhibit protein synthesis by the ribosome in a context-dependent manner. The word ‘interdict’ means to intercept, cut off, or destroy firepower to stop or hamper an enemy. Interdictors™ prevent disease-causing proteins from being synthesized before they even have a chance to enter the cell and cause harm.
Together, our scientific team, advisors, founders and investors are committed to advance the novel Interdictor™ modality and provide breakthrough treatments for patients with high, unmet medical need in oncology and neurodegenerative diseases.
LEADERSHIP Team

Larry Hamann, Ph.D.
Co-founder, President & CEO

Cassandra Choe-Juliak, M.D.
CMO

Michael Geremia, M.B.A.
CFO
Scientific Advisors

Danica Fujimori, Ph.D.
Co-founder
UCSF

James Fraser, Ph.D.
Co-founder
UCSF

Alan Ashworth, Ph.D., F.R.S.
Scientific advisor
UCSF

Pamela Munster, M.D.
Scientific advisor
UCSF

Donald McDonnell, Ph.D.
Scientific advisor
Duke University

Andrew C. Hsieh, M.D.
Scientific advisor
Fred Hutchinson Cancer Center

Dean Felsher, M.D., Ph.D.
Scientific advisor
Stanford University

Tom Rovis, Ph.D.
Scientific advisor
Columbia University
Board of directors

Mariana Mihalusova, Ph.D.
Board Director
Venrock

Bryan Roberts, Ph.D.
Board Observer
Venrock

Dave Maki, J.D.
Board Director
Altitude Life Science Ventures

Larry Hamann, Ph.D.
Board Director
Interdict
Investors


